Catechol-O-methyltransferase and its role in catecholamine metabolism. 1990

N Nic a' Bháird, and R Goldberg, and K F Tipton
Department of Biochemistry, Trinity College, Dublin, Ireland.

UI MeSH Term Description Entries
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002394 Catechol O-Methyltransferase Enzyme that catalyzes the movement of a methyl group from S-adenosylmethionone to a catechol or a catecholamine. Catechol Methyltransferase,Catechol-O-Methyltransferase,Catechol O Methyltransferase,Methyltransferase, Catechol,O-Methyltransferase, Catechol
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson
D065098 Catechol O-Methyltransferase Inhibitors Compounds and drugs that inhibit or block the activity of CATECHOL O-METHYLTRANSFERASE enzymes. Drugs in this class are used in management of central nervous system disorders such as PARKINSON DISEASE. Catechol O Methyltransferase Inhibitors,O-Methyltransferase Inhibitors, Catechol

Related Publications

N Nic a' Bháird, and R Goldberg, and K F Tipton
January 2002, The European journal of neuroscience,
N Nic a' Bháird, and R Goldberg, and K F Tipton
October 1990, Clinical pharmacology and therapeutics,
N Nic a' Bháird, and R Goldberg, and K F Tipton
January 1992, Reviews of physiology, biochemistry and pharmacology,
N Nic a' Bháird, and R Goldberg, and K F Tipton
October 1997, Journal of neurochemistry,
N Nic a' Bháird, and R Goldberg, and K F Tipton
September 1981, Science (New York, N.Y.),
N Nic a' Bháird, and R Goldberg, and K F Tipton
January 1981, Methods in enzymology,
N Nic a' Bháird, and R Goldberg, and K F Tipton
January 1974, International pharmacopsychiatry,
N Nic a' Bháird, and R Goldberg, and K F Tipton
January 2007, CNS drug reviews,
N Nic a' Bháird, and R Goldberg, and K F Tipton
January 1994, Journal of neural transmission. Supplementum,
N Nic a' Bháird, and R Goldberg, and K F Tipton
January 2010, International review of neurobiology,
Copied contents to your clipboard!